ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2022
National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points.
Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Recent Advances in Pyrazole-Based Cholinesterase Inhibitors: Medicinal Chemistry Perspectives from 2020 to 2025.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Bridging Research, Policy, and Practice: Advancing Evidence-Informed Approaches for Dementia Care and Prevention: an expert review by the Health Policy Professional Interest Area from ISTAART.Alzheimer's & dementia. Behavior & socioeconomics of aging · 2026Article
- Small Business Grants Awarded by the National Institutes of Health for Rhinologic Diseases, 1985-2024.International forum of allergy & rhinology · 2026Article
- Heterogeneous treatment effects of sodium-glucose cotransporter 2 inhibitors on risk of dementia in people with type 2 diabetes: A population-based cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Heterogeneous treatment effects of metformin on risk of dementia in patients with type 2 diabetes: A longitudinal observational study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Observational
- Recruitment of family caregivers of persons with dementia: Lessons learned from a pilot randomized controlled trial.Frontiers in pain research (Lausanne, Switzerland) · 2023Article
- A classification for complex imbalanced data in disease screening and early diagnosis.Statistics in medicine · 2022Article
- National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Review
- An analysis of the Clinical and Translational Science Award pilot project portfolio using data from Research Performance Progress Reports.Journal of clinical and translational science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe National Institute on Aging (NIA) provides funding to academic researchers and small businesses working in the Alzheimer's Disease (AD) and AD-related dementia (ADRD) fields to help commercialize their products. The NIA uses Small Business Innovation Research (SBIR) awards to bridge the funding gap in the diagnostic, therapeutic, and care interventions areas, enabling startups to reach key value inflection points to achieve scientific milestones.
methodsOnly publicly available information is reported. The National Institutes of Health Report Portfolio Online Reporting Tool database and the commercial database Global Data, were used to track the progress of companies that received SBIR or Small Business Technology Transfer (STTR) funding from the NIA.
resultsSince 2008, the NIA has awarded $280 million-including $207 million from fiscal year (FY) 2015 to FY 2019-in new small business program awards for AD/ADRD research. DISCUSSION: NIA seed capital and mentoring programs are critical resources to help small businesses reach key value inflection points and advance their research from concept to commercialization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.